First Mature Estimation of Median OS for Selpercatinib in Patients with RET Fusion-Positive NSCLC By Ogkologos - March 12, 2025 584 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from final efficacy and safety analyses from the LIBRETTO-001 study Source RELATED ARTICLESMORE FROM AUTHOR Patient Guide on Cancer Pain Management Now Available Also in French FDA Approves Pembrolizumab with Enfortumab Vedotin-ejfv for Muscle Invasive Bladder Cancer Postneoadjuvant Trastuzumab Deruxtecan Results in Higher Likelihood of iDFS Among Patients with HER2-positive EBC with Residual Invasive Disease After Neoadjuvant Treatment MOST POPULAR Rare Disease Day: Raising Awareness for Rare Cancers February 26, 2021 FDA Approves Brexucabtagene Autoleucel for Relapsed or Refractory B-Cell Precursor Acute... October 7, 2021 EMA Adopts a Positive Opinion for a New Indication for Pembrolizumab August 24, 2023 A Combination of Trastuzumab with Gemcitabine and Cisplatin Shows Promising Activity... November 24, 2023 Load more HOT NEWS Delivering the future of paediatric brain tumour therapy Cancer Survivor Kicked Out Of Bridal Party Cause She Refused To... Closing the gap: How new screening interventions could reduce inequalities in... Two Large Studies with New Screening Tests Show Promise for Increasing...
